Moxap LP Eye Drop is a sterile, preservative-free, aqueous solution for topical ophthalmic use. Each mL of the solution contains loteprednol etabonate 0.5% w/v and moxifloxacin 0.5% w/v. It is indicated for the treatment of conjunctivitis, including bacterial and inflammatory components, as well as for the treatment of post-operative conjunctival inflammation. The product combines the anti-inflammatory properties of loteprednol etabonate with the antibacterial activity of moxifloxacin, providing a broad-spectrum therapeutic effect. The loteprednol etabonate component helps to reduce the inflammation and pain associated with conjunctivitis, while the moxifloxacin component targets a wide range of bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Moxap LP Eye Drop is administered three to four times a day, and the recommended treatment duration is up to 7 days. It is contraindicated in patients with a history of herpes simplex keratitis or fungal keratitis, and in patients with known hypersensitivity to any of the components.